Please wait while we open this resource.
K
Lecture slides
USE OF SGLT2I IN THE MANAGEMENT OF T2DM, HF & CKD
Microlabs
PDF33 pages4.0 MB
The presentation provides an in-depth analysis of SGLT2 inhibitors, focusing on their mechanisms of action in glucose reabsorption and their therapeutic effects on patients with T2DM, HF, and CKD. It highlights significant clinical trials that demonstrate the efficacy of these medications in improving patient outcomes. Additionally, the document addresses the accessibility and pricing of Tilyptin, a DPP-4 inhibitor, in various regions of Uganda, emphasizing its role in diabetes management.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
Management of Hyperglycaemic Crises: DKA and HHS
Same clinical topic · Endocrinology
POSITIONING OF NEWER DRUGS IN T2D DIABETES CARE
Same clinical topic · Endocrinology
INSULIN SECRETION
Same clinical topic · Endocrinology
PHENOTYPE BASED APPROACH TO T2D
Same clinical topic · Endocrinology
diabetic emergencies
Same clinical topic · Endocrinology
HUMAN INSULIN CARAVAN
Same clinical topic · Endocrinology
DIAGNOSIS AND EVALUATION OF DIABETES PPT
Same clinical topic · Endocrinology
THYROTOXICOSIS AND OTHER THYROID DISEASES
Same clinical topic · Endocrinology
THYROTOXICOSIS AND OTHER THYROID DISEASES
Same clinical topic · Endocrinology